REPL vs TLRY · $825.7M cap vs rev $821.3M
Replimune Group Inc (REPL) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
REPL does not have a complete income-statement cache yet.
Latest reported TLRY revenue for 2025-05-31 was $821.3M. Net income was -$2.18B. Revenue was up 4.1% from 2024-05-31 to 2025-05-31. TLRY currently screens at market cap $573.9M.
REPL currently screens at market cap $825.7M. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the REPL and TLRY stock pages for the full models.
Not investment advice.